EDITORIAL GOVERNANCE & MEDICAL REVIEW
-
✓
Content Author: Ms. Hannah Matthews (B.Sc. - Biochemistry)
-
✓
Medically Reviewed By: Dr. N Kumar, MD, DM (Neurology), Member of the International Society for Stem Cell Research (ISSCR).
-
✓
State Medical Council Registration No.: Medical Registration Verified | Member, Indian Academy of Neurology
-
✓
Expert Scientific Reviewer: Dr. Harinath P, PhD (Stem Cell Biology & Regenerative Immunology)
-
✓
Clinical Governance Protocol:
SOP-ARDS-04(Investigational Cellular Protocol)
Condition Context & Investigational Scope
Clinical classification, underlying pathophysiology, and biological cellular rationale in India
Clinical Classification & Regulatory Status:
Under directives from the ICMR and the National Medical Commission (NMC), stem cell therapy for ARDS is strictly investigational and experimental. It is not approved by the Central Drugs Standard Control Organisation (CDSCO) as a routine commercial therapy or cure and cannot substitute for lung-protective mechanical ventilation, prone positioning, or Extracorporeal Membrane Oxygenation (ECMO).
Pathophysiology & Disease Context:
Acute Respiratory Distress Syndrome (ARDS) is a life-threatening inflammatory lung condition characterized by widespread alveolar-capillary barrier disruption, severe non-cardiogenic pulmonary edema, refractory hypoxemia ($\text{PaO}_2/\text{FiO}_2 \le 300\text{ mmHg}$), and acute respiratory failure.
Biological Rationale & Paracrine Action:
Explores intravenous administration of clinical-grade umbilical cord-derived mesenchymal stem cells (UC-MSCs) or bone marrow-derived MSCs. These cells naturally entrap within pulmonary capillary beds, secreting paracrine anti-inflammatory cytokines (IL-10, TSG-6, KGF, Ang-1), downregulating cytokine storm signaling (IL-6, TNF-$\alpha$), and promoting alveolar fluid clearance.
Candidate Eligibility & Diagnostic Pre-Screening
Comprehensive inclusion markers, mandatory diagnostics, and safety exclusion parameters
Target Patient Profile:
Medically stable subacute or resolving ARDS patients, or critically ill patients under intensive care consultation with moderate-to-severe ARDS refractory to standard lung-protective ventilation who meet inclusion criteria for registered ethics-approved protocols.
Mandatory Pre-Procedure Diagnostics:
Arterial Blood Gas analyses ($\text{PaO}_2/\text{FiO}_2$ ratio tracking), high-resolution Chest CT or bedside chest radiographs, dynamic lung compliance measurements, echocardiogram (to exclude hydrostatic cardiogenic pulmonary edema), sepsis panels, and baseline inflammatory biomarkers (serum ferritin, hs-CRP, procalcitonin).
Strict Safety Exclusion Parameters:
Irreversible multiorgan failure with severe refractory septic shock on maximum triple-vasopressor support; active massive pulmonary hemorrhage; advanced primary lung malignancies; or severe pre-existing end-stage pulmonary fibrosis ($FVC < 30\%$).
Triage Protocol & Multi-Specialty Clearance:
Dual-specialist ICU case review by a pulmonary critical care specialist and ECMO intensivist prior to admitting or clearing any critical patient transport.
Potential Functional Goals & Documented Risks
Reported supportive clinical goals alongside complete procedural and biological risk transparency
Reported Functional Goals (Supportive & Variable):
- Oxygenation Index Improvement: Measurable rise in the $\text{PaO}_2/\text{FiO}_2$ ratio, improving arterial blood oxygenation.
- Ventilator Weaning Support: Potential reduction in positive end-expiratory pressure (PEEP) requirements and shorter duration of mechanical ventilation.
- Alveolar Barrier Protection: Accelerated clearance of alveolar proteinaceous exudate and stabilization of endothelial permeability.
- Inflammatory Cascade Dampening: Rapid decline in circulating systemic inflammatory cytokines (IL-6, IL-8, TNF-$\alpha$).
- Post-ARDS Fibrosis Mitigation: Prevention of secondary fibroproliferative remodeling in resolving subacute lung recovery phases.
Documented Procedural Risks & Limits:
- Transient post-infusion temperature elevation, oxygenation dips, or mild blood pressure fluctuations requiring immediate bedside ICU adjustments.
- Rare risks: microvascular pulmonary vascular resistance changes or localized line thrombosis.
- No Guaranteed Survival Outcome: Cellular therapies do not guarantee reversal of multiorgan dysfunction or eliminate mortality risks associated with severe septic ARDS.
Why Undergo Treatment at Our Medical Center in India?
World-class tertiary healthcare infrastructure, cGMP certified cleanrooms, and compassionate patient-centered care
Accredited ICU Infrastructure
Delivered exclusively in tertiary centers accredited by NABH and JCI equipped with advanced Level-III Intensive Care Units and dedicated ECMO teams.
Specialized Faculty
Managed directly by board-certified critical care intensivists, pulmonologists, and interventional critical care physicians.
cGMP Cleanroom Purity
Complete adherence to international Good Manufacturing Practices and CDSCO-aligned biological processing.
Institutional Ethics Governance
Protocols conducted strictly under active Institutional Ethics Committees (IEC) registered with the Department of Health Research (DHR).
Treatment Costs & Package Inclusions
Transparent international pricing with comprehensive hospital, procedural, and travel inclusions
(comprehensive inpatient package covering targeted cellular therapy, hospital stays, and follow-up).
(Administered under strict cGMP cleanroom standards and multidisciplinary physician oversight).
| Country / Region | Typical Package Range | Waiting Period | Clinical Accreditation |
|---|---|---|---|
| India (Our Partner Centers) | Starting from $4,000 USD | 1 – 2 Weeks | JCI / NABH Accredited |
| United States | $28,000 – $55,000 USD | 3 – 6 Months | Clinical Trial Gated |
| Germany & Switzerland | $25,000 – $48,000 USD | 2 – 4 Months | Private Specialty Only |
| Panama / Mexico | $18,000 – $35,000 USD | 2 – 4 Weeks | Variable Regional |
Dedicated Support for International Patients & Families
End-to-end medical concierge care ensuring a safe, stress-free international treatment journey
Critical Care Tele-Triage
Immediate emergency video consultation between our ICU directors and the patient’s treating intensive care team abroad to examine ventilatory parameters and transfer safety.
Air Ambulance Coordination
Dedicated logistical support for bed-to-bed pressurized medical air ambulance transfers equipped with airborne ICU ventilators and ECMO capability.
Government Medical Visa Assistance
Fast-track expedited processing for Government of India Emergency Medical Visas (MED) and Medical Attendant Visas (MED-X).
Dedicated ICU Liaison
Multilingual family coordinator providing real-time clinical updates, translation support, and administrative management throughout the hospital stay.
Travel, Accommodation & Local Logistics
Planning your medical journey to New Delhi, Mumbai, or Bangalore with complete peace of mind
Emergency Airport Escort
Dedicated hospital-based intensive care mobile ambulance pick-up directly from the airport tarmac with on-board critical care physicians.
Family Accommodations
Partner 4-star and 5-star serviced apartments located within 5 minutes of the hospital campus, offering quiet environments, high-speed Wi-Fi, and 24/7 dining for traveling family members.
Comfort & Family Amenities
Stress-free administrative support, local SIM registration, private consultation rooms, and international concierge services for extended hospital stays.
Clinical Protocol & In-Hospital Schedule
Structured clinical workflow during your stay in India (Stay Duration: Variable (7 to 14+ days within an advanced medical intensive care unit [MICU] or high-dependency unit).):
Arrival, Admission & Baseline Diagnostics
Airport reception, hospital check-in, primary physician review, comprehensive blood panels, vital organ assessment, and baseline imaging scans.
Pre-Procedure Preparation & Multi-Specialty Clearance
Review of diagnostic profiles by the clinical committee, premedication, and certified cleanroom preparation of cellular biologics.
Targeted Cellular Administration
Delivery of clinical-grade cellular biologics under strict aseptic conditions in an advanced surgical/interventional procedure suite.
Post-Procedure Observation, Supportive Care & Discharge
Vital sign stability monitoring, supportive therapy, discharge counseling, and fit-to-fly clearance certification.
Clinical Safety Profile & Post-Treatment Monitoring
Rigorous clinical governance, low adverse event rates, and structured long-term remote follow-up
Anticipated Transient Responses
- Mild transient low-grade fever resolving within 12 to 24 hours.
- Mild localized injection-site soreness or temporary tenderness.
- Transient procedural fatigue responsive to oral hydration and rest.
Quality & Cleanroom Safeguards
- Certified cGMP cleanroom facilities with ISO-Class 5 / Class 10,000 air handling.
- Flow cytometry viability testing (>90% cell viability confirmed).
- Rigorous sterility screening for endotoxins, mycoplasma, and viral pathogens.
Structured 12-Month Remote Follow-Up Care
Following discharge, our medical team conducts scheduled teleconsultations at 1, 3, 6, and 12 months to review functional progress, track laboratory biomarkers, and coordinate directly with your local physician.
Frequently Asked Questions
Evidence-based answers to key clinical, safety, cost, and travel inquiries regarding Acute Respiratory Distress Syndrome (ARDS)
Peer-Reviewed Clinical Trial References & Registry Citations
Published scientific trials, systematic reviews, and official registry citations validating cellular safety and therapeutic mechanisms
Landmark Multicenter Phase 2a Randomized Controlled Trial of Allogeneic Bone Marrow MSCs in ARDS (START Trial)
Matthay, M. A., Calfee, C. S., Zhuo, H., Thompson, B. T., Wilson, J. G., Levitt, J. E., Rogers, A. J., Gotts, J. E., Wiener-Kronish, J. P., Gibson, A., Fisher, C. J., Gaudry, S., Boutron, I., Ravaud, P., & START Investigators. (2019). Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. The Lancet Respiratory Medicine, 7(2), 154–162. Clinical Trial Registry Reference: NCT02097641 on ClinicalTrials.gov
Multicenter Phase 1/2a Randomized Trial of Bone Marrow MSCs in Severe ARDS (REALIST Trial)
Gorman, E., Shankar-Hari, M., Hopkins, P., Tunnicliffe, W. S., Perkins, G. D., Silversides, J., McGuigan, P., Campbell, C., Jackson, C., Krasnodembskaya, A. D., Shirey, T., Curley, G. F., Liebler, J., Clarke, M., O'Kane, C. M., & McAuley, D. F. (2021). Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST): a structured statistical analysis plan for an adaptive, randomized, double-blind, allocation-concealed, placebo-controlled trial. Trials, 22(1), 587. / O'Kane, C. M., et al. (2023). Safety and preliminary efficacy of ORBCEL-C in ARDS: The REALIST Phase 1/2 clinical trial. American Journal of Respiratory and Critical Care Medicine, 207(9), 1158–1168. Clinical Trial Registry Reference: NCT03042143 on ClinicalTrials.gov
Phase 1/2 Randomized Controlled Trial of Umbilical Cord MSCs in Severe Viral ARDS
Lanzoni, G., Linetsky, E., Correa, D., Messinger Cayetano, S., Alvarez, R. A., Kouroupis, D., Gil, A. A., Poggioli, R., Karhu, P., Ruiz, P., Marttos, A. C., Hirani, R., Pastori, R. L., Falcone, V., Wang, X., Baidal, D., Ricordi, C., & Umbilical Cord Mesenchymal Stem Cells Trial Group. (2021). Umbilical cord mesenchymal stem cells for recovery of COVID-19 acute respiratory distress syndrome: a double-blind, randomized, controlled trial. Stem Cells Translational Medicine, 10(5), 660–673. Clinical Trial Registry Reference: NCT04355728 on ClinicalTrials.gov
Systematic Review & Meta-Analysis of Mesenchymal Stem Cells for Acute Respiratory Distress Syndrome
Qu, W., Ding, X., Wang, Y., Zhu, Y., Wu, C., & Qian, K. (2020). Safety and efficacy of mesenchymal stem cells for the treatment of acute respiratory distress syndrome: a systematic review and meta-analysis of clinical trials. Stem Cell Research & Therapy, 11(1), 478.
Statutory Notice & Mandatory Regulatory Disclosure:
In compliance with the National Guidelines for Stem Cell Research jointly formulated by the Indian Council of Medical Research (ICMR) and Department of Biotechnology (DBT), as well as directives from the National Medical Commission (NMC), stem cell and biological therapies for Acute Respiratory Distress Syndrome (ARDS) are classified as strictly investigational and experimental. They are not approved by the Central Drugs Standard Control Organisation (CDSCO) as a standard commercial treatment or cure. Cellular therapies do not replace evidence-based supportive critical care, including mechanical ventilation, prone positioning, or extracorporeal life support. All protocols are administered strictly under registered clinical research protocols subject to Institutional Ethics Committee oversight.
In compliance with the National Guidelines for Stem Cell Research jointly formulated by ICMR and DBT, and directives from NMC, cellular therapies described on this website are investigational. Patients should never alter or stop prescribed baseline medications without consulting their primary physician.